A new immune cell therapy for melanoma, lung, and cervical cancer
Part of Cancer, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new way to boost your immune cells after they are collected from your tumor and grown in a lab. Instead of high-dose IL-2, you would get a modified version called ANV419, which may have fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these cancers: melanoma, non-small cell lung cancer, or cervical cancer that has spread or cannot be removed by surgery.
- Your cancer has gotten worse after at least one standard treatment (or you cannot have standard treatment).
- You have a tumor that can be removed or biopsied to collect immune cells, and you still have other measurable cancer after that.
- You are 18 or older, able to care for yourself (ECOG 0 or 1), and have adequate organ function (heart, lungs, blood, liver, kidneys).
- You have no active infections, autoimmune diseases, or other cancers (except some minor ones) and no serious heart or lung problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a lab-made immune cell treatment (TIL) boosted with CD40L, plus nivolumab, for stage IV or returning non-small cell lung cancer with specific gene changes (EGFR, ALK, ROS1, or HER2). It aims to help your immune system attack the cancer after it has grown despite standard treatments.
This trial tests a personalized cell therapy using your own immune cells (TILs) grown in a lab. It is for people with advanced melanoma that did not respond to or stopped responding to prior immunotherapy.
This trial tests a new way to treat advanced melanoma by taking immune cells from your tumor, enhancing them in the lab to fight better, and giving them back to you. It is for people whose melanoma has spread or cannot be removed, and who have already tried standard treatments.
This Phase 1 study tests LM103 to treat advanced cancers that are not responding to standard treatment. It also looks at whether enough tumor tissue can be collected for immune cell testing, and focuses on safety at first.
This trial tests a new treatment called ADP-TILIL7 for people with advanced melanoma. It uses your own immune cells (T-cells) that are taken from a tumor, multiplied in a lab, and then given back to you to fight the cancer. The goal is to see if this treatment is safe and works better than standard options.
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.